HuGE Literature Finder
Records
1
-
3
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO open 2020 Dec 6 (1): 100019. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes A A, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino |
Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer. Pharmacological research 2017 Aug . Lam Siu W, van der Noort Vincent, van der Straaten Tahar, Honkoop Aafke H, Peters Godefridus J, Guchelaar Henk-Jan, Boven Ep |
Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis. Hepato-gastroenterology 0 59 (117): 1609-13. Kasuya Kazuhiko, Tsuchida Akihiko, Nagakawa Yuichi, Suzuki Yoshiaki, Suzuki Minako, Aoki Tatsuya, Abe Yuta, Shimazu Motohide, Itoi Takao, Sofuni Atsus |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 31, 2023
- Content source: